|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
ABSTRACT |
|---|
|
|
|---|
Exhaled nitric oxide (NO) remains a promising noninvasive index
for monitoring inflammatory lung diseases; however, the plateau concentration (CNO,plat) is nonspecific and requires a constant exhalation flow rate. We utilized a new technique that employs a variable flow rate to estimate key flow-independent parameters characteristic of NO exchange in a group (n = 9) of 10 to 14 yr-old healthy children and children with cystic fibrosis (CF): maximum flux
of NO from the airways (JNO,max, pl s
1), diffusing capacity of NO in
the airways (DNO,air, pl s
1 ppb
1), steady-state alveolar concentration (Calv,ss, ppb), and mean tissue concentration of NO in the airways
(Ctiss,air, ppb). We determined the following mean (± SD) values in
the healthy children and patients with CF for JNO,max, DNO,air, Calv,ss,
and Ctiss,air, respectively: 784 ± 465 and 607 ± 648 pl s
1; 4.82 ± 3.07 and 17.6 ± 12.1 pl s
1 ppb
1; 4.63 ± 3.59 and 1.96 ± 1.18 ppb; and
198 ± 131 and 38 ± 25 ppb. DNO,air is elevated (p = 0.007), and
both Calv,ss and Ctiss,air are reduced (p = 0.05 and 0.002, respectively) in CF. In contrast, CNO,plat for healthy control subjects and
patients with CF are not statistically different at both exhalation
flow rates of 50 ml/s (17.5 ± 11.5 and 11.5 ± 8.97) and at 250 ml/s
(7.11 ± 5.36 and 4.28 ± 3.43). We conclude that DNO,air, Ctiss,air,
and Calv,ss may be useful noninvasive markers of CF.
| |
INTRODUCTION |
|---|
|
|
|---|
Keywords: nitric oxide; parameter estimation; airways; inflammation; healthy children
Nitric oxide (NO) is an important endogenous mediator that arises from the airways and alveoli and can be detected in the exhaled breath (1, 2). Several inflammatory disorders, such as asthma, are associated with elevated exhaled NO concentrations (3). Although plateau NO concentration (CNO,plat) in patients with cystic fibrosis (CF), a congenital lung disease marked by inflammation, has been reported to be decreased (7), it has also been reported to be unchanged (5, 6, 10) when compared with healthy control subjects. These paradoxical results for CF can be explained potentially by both real alterations in the underlying physiology due to differences in disease penetration, duration of disease, types of colonizing organisms, and the coexistence of atopy or asthma, as well as differences in the experimental protocol (e.g., variation in exhalation flow rate) (14, 15).
CNO,plat may not be a specific or sensitive indicator of NO
exchange dynamics in CF, because in and of itself, CNO,plat provides little or no anatomic information. We have recently described a new, simple, and robust technique that utilizes a preexpiratory 20-s breathhold followed by decreasing flow rate
(~ 6-1% vital capacity/s) maneuver to simultaneously determine several key flow-independent parameters that could reveal underlying physiological mechanisms (16): maximum flux
of NO from the airways (JNO,max, pl s
1), diffusing capacity of
NO in the airways (DNO,air, pl s
1 ppb
1), steady-state alveolar
concentration (Calv,ss, ppb), and mean (over radial position)
concentration of NO within the tissue phase (Ctiss,air, ppb, equal
to the ratio JNO,max/DNO,air). These provide potentially useful and
reproducible information regarding net production and diffusion of NO in the airways and alveolar regions of the lungs.
Thus, by providing a more detailed description of NO exchange dynamics throughout the lung, we hypothesize that this new technique will distinguish NO exchange dynamics in
patients with CF from healthy children.
| |
METHODS |
|---|
|
|
|---|
Subjects
Nine healthy children and nine children with previously diagnosed CF (ages 10-14) participated in this study. Subjects were categorized as healthy on the basis of standard spirometry (FEV1 > 75% of predicted on the basis of their race, age, and height) and no clinical history of chronic lung disease. Subject characteristics are presented in Table 1 including details of their clinical history. The Institutional Review Board at the University of California, Irvine approved the protocol, and informed consent was obtained from subjects and parents.
|
Experimental Protocol
Forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) were measured in all subjects (Vmax229; Sensormedics, Yorba Linda, CA) by using the best performance (see Table 1) from three consecutive maneuvers before measuring the indices of NO exchange dynamics.
Each subject performed two types of exhalation maneuvers: (1) vital capacity maneuvers in triplicate at a constant exhalation flow of ~ 50 ml/s and ~ 250 ml/s according to the ATS (American Thoracic Society) and the ERS (European Respiratory Society) (17, 18) to determine CNO,plat without breathhold; (2) five repetitions of a 20-s preexpiratory breathhold followed by a decreasing flow rate maneuver (16). During the breathhold, a positive pressure of > 5 cm H2O was maintained to prevent nasal contamination (17). A schematic of the experimental apparatus has been previously presented (16). After the breathhold, the exhalation valve was opened allowing the patient to expire. The expiratory flow rate progressively decreased during the exhalation from 6% to 1% of vital capacity per second using a Starling resistor (Hans Rudolph Inc., Kansas City, MO) with a variable resistance.
Airstream Analysis
A chemiluminesence NO analyzer (NOA280; Sievers, Inc., Boulder, CO) was used to measure the exhaled NO concentration. The instrument was calibrated on a daily basis using a certified NO gas (45 ppm in N2; Sievers, Inc.). The zero point calibration was performed with an NO filter (Sievers, Inc.) and done immediately before the collection of a profile. The flow rate and pressure signals were measured using a pneumotachometer (RSS100; Hans Rudolph Inc.). The pneumotachometer was calibrated daily and was set to provide the flow in units of STPD and pressure in units of mm Hg.
Parameter Estimation and Data Analysis
A previously described two-compartment model was used to estimate
the four key flow-independent parameters in healthy children and patients with CF (16, 19). Only three of the four parameters are independent, as Ctiss,air is the ratio of two of the other parameters, maximum total volumetric flux per unit airway volume (pl/s) of NO from
the airway wall (JNO,max)/diffusing capacity (pl s
1 ppb
1) of NO in the
airways (DNO,air). Figure 1 is a simple schematic of the two-compartment model and flow-independent parameters. Mathematical estimation of the parameters (Calv,ss, DNO,air, JNO,max) has been previously described in detail (16), and is accomplished by nonlinear least-square
minimization utilizing a conjugated direction minimization algorithm.
|
The alveolar region is characterized by the steady-state alveolar concentration, Calv,ss (19, 20). Upon exhalation, the air passes through the airway tree and additional NO is transferred from the airway tissue. This additional volume of NO is referred to as the flux of NO from the airways, volumetric flux of NO (JNO) (pl/s), and is not a constant, but a linear function of the gas phase concentration (19, 21, 22):
|
(1) |
Thus, airway compartment is not well mixed, but the concentration depends on the axial or longitudinal direction and is characterized by two parameters: JNO,max and DNO,air. JNO,max is the maximum flux of NO from the airway tissue, which is equal to the airway compartment flux if the gas phase concentration, concentration (ppb) of NO in the airway compartment (Cair), were zero.
An alternative presentation of the three flow-independent parameters includes the use of the mean (over radial position) tissue concentration in the airways, Ctiss,air, instead of JNO,max (22). Ctiss,air is simply the ratio JNO,max/DNO,air. This is more easily demonstrated by expressing JNO in an alternate but equivalent form to Equation 1 (16, 21, 22):
|
(2) |
Note that JNO,max is simply the product DNO,air · Ctiss,air. In Equation 2, JNO is expressed as proportional to the appropriate concentration difference between the airway tissue (Ctiss,air) and the gas stream (Cair). The coefficient of proportionality is DNO,air. Thus, DNO,air can be interpreted as a conductance for mass transfer of NO between the airway tissue and the gas phase.
Figures 2A (healthy) and 2C (CF) are representative experimental exhalation profiles as well as the model simulation. Figures 2B (healthy) and 2D (CF) are the corresponding exhaled volume, flow, and pressure tracings. The model does not predict phase I and II of the exhalation profile, where the accumulated NO during breathholding in the conducting airways and transition region of the lungs exits the mouth. This discrepancy is attributed to axial diffusion that our model neglects. Although the precise shape of phase I cannot be accurately simulated with the model, the absolute amount of NO in phase I and II can be predicted. Thus, our technique utilizes the information from phase I and II by forcing the model to simulate the total amount of NO eliminated in phase I and II (area under the curve as depicted in Figures 2A and 2C) of the exhalation in addition to simulating the precise exhaled concentration (ppb) (Cexh) over phase III. To ensure complete emptying of the airway compartment after breathhold, we define the transition from phase II and III as the point in the exhalation for which the slope (dCexh/dV) of the exhalation profile is zero.
|
We assessed the ability of the model to simulate the profile by comparing the area under the curve in phase I and II in the experimental and theoretical data. Figure 3 presents the percentage of the experimental area under the curve predicted by the model for all 45 breathing maneuvers (nine subjects times five repeated maneuvers). It is evident that there are a few outliers (solid circles, < 80% of the experimental area under the curve) in each population, which represent profiles that the two-compartment model cannot adequately simulate. These profiles were subsequently discarded. There were no more than two discarded profiles from any individual subject. Thus, the population mean values for each of the parameters for the healthy children and patients with CF are based on exhalation profiles in which the model-predicted area under the curve for phase I and II is > 80% of the experimental area under the curve.
|
The intramaneuver (superscript m), intrasubject (superscript s), and
intrapopulation (superscript p) variability have been described previously (16), and will be characterized by the 95% confidence interval
expressed as a percentage of the estimated parameter value, intramaneuver 100(1
)% confidence interval (CIm), intrasubject 100(1
)%
confidence interval (CIs), and intrapopulation 100(1
)% confidence
interval (CIp), respectively. CNO,plat and the flow-independent parameters are expressed as a mean and 95% confidence interval (CI). To determine the relation between pulmonary function (FVC and FEV1/
FVC) and the estimated three flow-independent parameters, linear
regression and correlation were performed. A p value of < 0.05 is
considered significant.
| |
RESULTS |
|---|
|
|
|---|
FVC, FEV1, FEV1/FVC, and the clinical history of the CF subjects are presented in Table 1. Seven of the nine subjects with CF had concurrent reactive airways diseases, and all of these subjects were currently taking inhaled corticosteroids. The two subjects who did not have reactive airways disease were taking only nasal corticosteroids. FVC and FEV1 were significantly lower in CF than in healthy children (p < 0.05). Means for each of the nine subjects in each category and the population mean are presented in Figure 4. In the nine children with CF, only six were able to complete the 20-s breathhold. In the three children who were not able to hold their breath for 20 s, one held their breath for 15 s, and two for 10 s. Estimated JNO,max is not significantly different between healthy control subjects and patients with CF (p = 0.52); however, DNO,air is significantly elevated (p = 0.007) and Calv,ss and Ctiss,air are significantly reduced (p = 0.05 and 0.002, respectively) in CF.
|
Mean values for CIp for healthy children and CF are 46% and 82%, 49% and 53%, 60% and 46%, and 51% and 51% for JNO,max, DNO,air, Calv,ss, and Ctiss,air, respectively. Thus, the variation across the population of healthy children and patients with CF is approximately the same for each of the parameters.
The population means of CIm and CIs for each parameter are presented in Figure 5 for the healthy control subjects and patients with CF. JNO,max and Calv,ss for healthy controls are estimated with high accuracy (population mean CIm = 38% and 97%, respectively) relative to DNO,air (population mean CIm = 128%). For CF, the population mean for CIm for the three flow-independent parameters are 118%, 167%, and 284% for JNO,max, DNO,air, and Calv,ss, respectively, which are much larger than the healthy children. In contrast to CIm, population mean values for CIs for each of the parameters are not statistically different between healthy control subjects and patients with CF, and range from 26% to 65% (Figure 5).
|
None of the flow-independent parameters had any significant correlation with standard indices of lung volume (FVC) or airway obstruction (FEV1/FVC) for both healthy children and patients with CF.
Mean CNO,plat (± CI) from the experimental maneuvers were 20.2 ± 10.1 ppb and 10.2 ± 3.97 ppb for healthy children and 8.91 ± 5.38 ppb and 4.79 ± 2.48 ppb for patients with CF at the target flow rates of ~ 50 ml/s and ~ 250 ml/s, respectively. The experimental values for each of the individuals are presented in Table 2 with model-predicted CNO,plat in parenthesis. CNO,plat at the targeted flow rate of 50 ml/s and 250 ml/s are lower for patients with CF when compared with healthy control subjects; however, the mean exhalation flow rates for patients with CF were larger in both cases (Table 2). Because a larger flow rate will decrease CNO,plat, one must attempt to control for this confounding variable. We used the estimated flow-independent parameters for each of the subjects to estimate CNO,plat using the two-compartment model (see governing equation in the Appendix ) at precisely an exhalation flow rate of 50 and 250 ml/s (Table 2). Mean CNO,plat (± CI) from the model were 17.5 ± 8.97 ppb and 7.11 ± 4.03 ppb for healthy children and 11.5 ± 6.89 ppb and 4.28 ± 2.64 ppb for patients with CF at 50 ml/s and 250 ml/s, respectively. The model-predicted CNO,plat are still lower for children with CF when compared with healthy children, but the difference is no longer significant (p > 0.05).
|
| |
DISCUSSION |
|---|
|
|
|---|
This study has estimated several flow-independent parameters characteristic of NO exchange dynamics in the lungs, which have not been measured in CF before, and compared these to the plateau concentration at a constant exhalation flow rate. When compared with healthy control subjects, we found differences in CNO,plat that were not significant if one controlled for differences in the exhalation flow rate. In contrast, the flow-independent parameters differed substantially between patients with CF and healthy control subjects. Thus, our new method provides greater sensitivity in distinguishing NO exchange dynamics between healthy control subjects and patients with CF.
The difference between CNO,plat and the flow-independent parameters is highlighted by examining the composite experimental and model-predicted exhalation profiles from the population of patients with CF and healthy control subjects (Figure 6). Figure 6A depicts the composite experimental profile for each population by taking the mean exhaled concentration at equivalent exhaled volumes. Figure 6B presents the composite model predicted profiles by using the average values for the flow-independent parameters in the model equation (see Appendix ). It is evident that there are small changes in the exhaled NO concentration during phase III due to small changes in Calv,ss and JNO. However, there are very large differences in the concentration of NO in phase I and II in which the differences in NO exchange dynamics between healthy control subjects and patients with CF are magnified during a breathhold. The magnification of the airway compartment allows one to estimate DNO,air, JNO,max, and Ctiss,air, achieve more detailed information regarding NO exchange dynamics, and distinguish healthy children from patients with CF.
|
Interpreting the significant increase in DNO,air observed in patients with CF requires understanding the factors that affect its value. Thicker and more viscous mucus present in patients with CF would tend to increase the diffusion distance for NO as well as the "ease" at which NO can diffuse. Both of these observations would decrease DNO,air and contrast with our experimental observation of an elevated DNO,air.
It has been previously hypothesized that inflammation may
increase the surface area of the airways producing NO by
stimulating the inducible form of nitric oxide synthase (iNOS)
(34, 35). This would increase DNO,air (proportional to surface
area, see Appendix ), which is consistent with our observation;
however, iNOS expression is reduced in epithelial cells from
patients with CF even though levels of inflammatory mediators such as tumor necrosis factor (TNF)-
and interleukin
(IL)-1
are increased in bronchoalveolar lavage (36). Furthermore, neutrophils, which increase iNOS expression in
normal cells, do not enhance the iNOS expression in CF epithelial cells (37).
The impact of chemical consumption of NO, as characterized by k (a first-order rate constant), is also a possibility. In vivo, NO reacts with several substrates including oxygen, protein thiols (e.g., glutathione), and superoxide. In CF, there are increased numbers of neutrophils, which can produce toxic radical species including superoxide. Normally, glutathione (GSH) provides an effective antioxidant role in the lung; however, in CF, the concentration of GSH has been reported to be decreased (23) as a result of abnormal GSH transport related to the defective CFTR (24). The presence of neutrophils and lower levels of GSH may provide an environment in which excess superoxide can react quickly with NO to form peroxynitrite and other more stable end products such as nitrite and nitrate (25, 26).
It has been postulated that the half life, t1/2, in vivo in
healthy control subjects is between the range of 0.1 to 10 s, which is equivalent to between 7 and 0.07 s
1 based on the
simple relationship k = ln(2)/t1/2 (the shaded region of Figure
7). Figure 7 plots a theoretical estimate of DNO,air (see Appendix
for details) as a function of k. DNO,air increases as k increases
(t1/2 decreases). The relationship is highly nonlinear: DNO,air is
independent of k for k < 1, but becomes a strong positive function of k for k > 10. The positive relationship between
DNO,air and k is due to an increase in the radial gradient of NO
concentration from chemical consumption and is a well-known
phenomenon in chemical reaction engineering (33).
|
The increase in chemical consumption of NO acts to increase DNO,air, or the conductance for mass transfer, but would decrease the mean tissue concentration, Ctiss,air. In addition, reduced iNOS expression would also tend to reduce Ctiss,air. Thus, the effect on DNO,air and Ctiss,air would tend to negate each other in terms of the impact on the actual flux of NO (JNO or JNO,max, see Equations 1 and 2) from the airways. Calv,ss is reduced in patients with CF, but this represents only 17-24% of CNO,plat at an exhalation flow rate of 50 ml/s. This provides a potential explanation for why some studies on CF have reported no statistical change, or a small decrease in exhaled NO concentration, and why the flow-independent parameters are potentially more sensitive. A patient with CF could have highly elevated DNO,air but greatly reduced Ctiss,air; thus, JNO and JNO,max are near normal, and a decrease in Calv,ss results in a small decrease in CNO,plat, which may not be detectable when compared with healthy control subjects (compare healthy subject #8 with CF subject #5). Figure 8 describes schematically the probable cascade of events in CF that leads to changes in the flow-independent parameters and little or no changes in the exhaled NO concentration as previously described.
|
It is important to note that asthma, or reactive airways disease, can also substantially impact NO exchange dynamics. Only two of the CF subjects (subjects #3 and #7) did not have concurrent reactive airways disease. However, these two subjects did not display remarkably different NO exchange parameters. One subject with CF had a very high JNO,max and DNO,air (subject #2). There was nothing remarkable in this subject's clinical history; however, this subject had by far the best lung function of the subjects with CF (see Table 1). The clinical significance of this relationship is not known.
The larger intramaneuver confidence interval in patients with CF (Figure 5) is due to the smaller lung volume (Table 1 and Figure 6), relative inhomogeneity of gas distribution, and magnitude of the exhaled NO signal. Even though the range of exhalation flow rates is scaled to the lung volume, a smaller lung volume results in a smaller absolute range of sampled flow rates. Thus, the smaller exhaled volume results in a smaller change in the exhaled NO signal with changing flow rate thereby decreasing the accuracy of the parameter estimate (based on the nonlinear least-square regression technique). In addition, the absolute exhaled concentration of NO tends to be smaller in CF, which decreases the signal-to-noise ratio of the analytical instrument.
As previously described, only six of the nine children with CF were able to complete the 20-s breathhold. Although a 20-s breathhold is desirable, it is not required. We have previously reported (16) theoretically and experimentally that the uncertainty of DNO,air decreases as the breathhold time increases up to 20 s. The estimation of DNO,air depends almost exclusively on the magnitude of the peak in phase I (see Figure 6), which increases with increasing breathhold time (16).
In spite of the differences observed with CIm, the intrasubject (CIs) variability is not significantly different between healthy control subjects and patients with CF (see Figure 4). This finding suggests that the reproducibility of the breathing maneuver does not depend on the presence of CF despite the fact that three of the children with CF were not able to hold their breath for 20 s. Each of these three children held their breath for approximately the same length of time for each of the breathing maneuvers.
The intrapopulation (CIp) variability did not differ between the healthy children and patients with CF, and is similar for all of the flow-independent parameters (range 46-82%). This variation within the population is much larger than other endogenous gases (e.g., CO2). The mechanisms underlying the intrapopulation variability both in health and disease are not known, but might be related to the presence of subclinical inflammation in healthy control subjects or genetically determined differences in NO metabolism as characterized by the length of a repeated polymorphism in the neuronal nitric oxide synthase gene in patients with CF (39, 40).
There are permanent structural changes that occur in the CF lung, particularly those related to anatomic and physiological deadspace. The physiological deadspace in CF is normal to slightly increased relative to healthy control subjects (41). Thus, our estimate of the airway compartment volume (volume of airway compartment [Vair, ml] Table 1), which is based on the subjects ideal body weight and age, may underestimate Vair. We have previously shown that DNO,air is the most sensitive of the three flow-independent parameters to the choice of Vair (16). The dependence is positive; that is, as Vair increases, the estimate of DNO,air also increases to compensate for the dilutional effect of the larger volume. Thus, a slightly larger Vair for children with CF would actually serve to increase the DNO,air further from the healthy control population. Nitrogen washout is a common method to estimate anatomical deadspace; however, the accuracy of this method is compromised by the presence of diseases that impact emptying patterns. The dependence of DNO,air on Vair may explain some of the intersubject variability, and suggests that intrasubject longitudinal changes in the flow-independent parameters may have the greatest clinical utility.
Another possible source of error is performing the spirometric breathing maneuvers before the NO breathing maneuver. According to Silkoff and coworkers (42) and Deykin and coworkers (43, 44), spirometry can depress exhaled NO levels by 10-36% from the baseline in healthy subjects and subjects with asthma by an unknown mechanism. This may perturb one or more of the flow-independent parameters, and should be considered in any future studies.
In summary, we have quantified flow-independent parameters characteristic of NO exchange dynamics in the lungs of healthy children and age-matched patients with CF. The airway diffusing capacity and tissue concentration are significantly different between the two populations and may be a more effective technique than the plateau concentration in distinguishing NO exchange in patients with CF from healthy control subjects. In addition, the flow-independent parameters are not correlated with standard spirometry, which suggests that they may provide additional information to the clinician regarding the inflammatory status of the airways and alveolar region in patients with CF. Their precise interpretation will not be known until future studies establish the correlation of these parameters with more established markers of inflammation obtained by more invasive means.
| |
Footnotes |
|---|
Correspondence and requests for reprints should be addressed to Steven C. George, M.D., Ph.D., Department of Chemical Engineering and Materials Science, 916 Engineering Tower, University of California, Irvine, Irvine, CA 92697-2575. E-mail: scgeorge{at}uci.edu
(Received in original form May 21, 2001 and accepted in revised form October 30, 2001).
Acknowledgments: The authors would like to thank the General Clinical Research Center (GCRC) at University of California, Irvine, and Dr. Eliezer Nussbaum at Miller Children's Hospital at Long Beach Memorial Medical Center for recruiting patients with CF.
Supported by grants from the National Institutes of Health (R29-HL60636, HD23969, and M01RR00827-S1).
| |
References |
|---|
|
|
|---|
1. Gustafsson LE, Leone AM, Persson MG, Wiklund NP, Moncada S. Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem Biophys Res Commun 1991; 181: 852-857 [Medline].
2. Silkoff PE, McClean PA, Caramori M, Slutsky AS, Zamel N. A significant proportion of exhaled nitric oxide arises in large airways in normal subjects. Respir Physiol 1998; 113: 33-38 [Medline].
3. Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J 1993; 6: 1368-1370 [Abstract].
4. Lundberg JO, Weitzberg E, Lundberg JM, Alving K. Nitric oxide in exhaled air. Eur Respir J 1996; 9: 2671-2680 [Abstract].
5. Dotsch J, Demirakca S, Terbrack HG, Huls G, Rascher W, Kuhl PG. Airway nitric oxide in asthmatic children and patients with cystic fibrosis. Eur Respir J 1996; 9: 2537-2540 [Abstract].
6.
Lundberg JO,
Nordvall SL,
Weitzberg E,
Kollberg H,
Alving K.
Exhaled nitric oxide in paediatric asthma and cystic fibrosis.
Arch Dis
Child
1996;
75:
323-326
7.
Kroesbergen A,
Jobsis Q,
Bel EH,
Hop WC,
de Jongste JC.
Flow-
dependency of exhaled nitric oxide in children with asthma and cystic
fibrosis.
Eur Respir J
1999;
14:
871-875
8.
Thomas SR,
Kharitonov SA,
Scott SF,
Hodson ME,
Barnes PJ.
Nasal and
exhaled nitric oxide is reduced in adult patients with cystic fibrosis and
does not correlate with cystic fibrosis genotype.
Chest
2000;
117:
1085-1089
9. Grasemann H, Michler E, Wallot M, Ratjen F. Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. Pediatr Pulmonol 1997; 24: 173-177 [Medline].
10.
Balfour-Lynn IM,
Laverty A,
Dinwiddie R.
Reduced upper airway nitric
oxide in cystic fibrosis.
Arch Dis Child
1996;
75:
319-322
11.
Corradi M,
Montuschi P,
Donnelly LE,
Pesci A,
Kharitonov SA,
Barnes PJ.
Increased nitrosothiols in exhaled breath condensate in inflammatory airway diseases.
Am J Respir Crit Care Med
2001;
163:
854-858
12.
Ho LP,
Innes JA,
Greening AP.
Nitrite levels in breath condensate of
patients with cystic fibrosis is elevated in contrast to exhaled nitric oxide.
Thorax
1998;
53:
680-684
13. Ho LP, Innes JA, Greening AP. Exhaled nitric oxide is not elevated in the inflammatory airways diseases of cystic fibrosis and bronchiectasis. Eur Respir J 1998; 12: 1290-1294 [Abstract].
14. Kharitonov SA, Barnes PJ. Nasal contribution to exhaled nitric oxide during exhalation against resistance or during breath holding. Thorax 1997; 52: 540-544 [Abstract].
15. Grasemann H, Ratjen F. Cystic fibrosis lung disease: the role of nitric oxide. Pediatr Pulmonol 1999; 28: 442-448 [Medline].
16.
Tsoukias NM,
Shin HW,
Wilson AF,
George SC.
A single-breath technique with variable flow rate to characterize nitric oxide exchange dynamics in the lungs.
J Appl Physiol
2001;
91:
477-487
17.
American Thoracic Society. Recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children
1999.
Am J Respir Crit Care Med 1999;160:2104-2117.
18. Kharitonov S, Alving K, Barnes PJ. Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force. Eur Respir J 1997; 10: 1683-1693 [Medline].
19.
Tsoukias NM,
George SC.
A two-compartment model of pulmonary nitric oxide exchange dynamics.
J Appl Physiol
1998;
85:
653-666
20.
Hyde RW,
Geigel EJ,
Olszowka AJ,
Krasney JA,
Forster RE 2nd,,
Utell MJ,
Frampton MW.
Determination of production of nitric oxide by
lower airways of humans
theory.
J Appl Physiol
1997;
82:
1290-1296
21.
Pietropaoli AP,
Perillo IB,
Torres A,
Perkins PT,
Frasier LM,
Utell MJ,
Frampton MW,
Hyde RW.
Simultaneous measurement of nitric oxide
production by conducting and alveolar airways of humans.
J Appl
Physiol
1999;
87:
1532-1542
22. Silkoff PE, Sylvester JT, Zamel N, Permutt S. Airway nitric oxide diffusion in asthma. Role in pulmonary function and bronchial responsiveness. Am J Respir Crit Care Med 2000;161(4, Part 1):1218-1228.
23.
Roum JH,
Buhl R,
McElvaney NG,
Borok Z,
Crystal RG.
Systemic deficiency of glutathione in cystic fibrosis.
J Appl Physiol
1993;
75:
2419-2424
24. Gao L, Kim KJ, Yankaskas JR, Forman HJ. Abnormal glutathione transport in cystic fibrosis airway epithelia. Am J Physiol 1999;277(1, Part 1):L113-L118.
25. Jones KL, Bryan TW, Jinkins PA, Simpson KL, Grisham MB, Owens MW, Milligan SA, Markewitz BA, Robbins RA. Superoxide released from neutrophils causes a reduction in nitric oxide gas. Am J Physiol 1998;275(6, Part 1):L1120-L1126.
26.
Shin H-W,
George SC.
Microscopic modeling of nitric oxide and S-nitrosoglutathione kinetics and transport in human airways.
J Appl Physiol
2001;
90:
777-788
27. Borok Z, Buhl R, Grimes GJ, Bokser AD, Hubbard RC, Holroyd KJ, Roum JH, Czerski DB, Cantin AM, Crystal RG. Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis. Lancet 1991; 338: 215-216 [Medline].
28.
Roum JH,
Borok Z,
McElvaney NG,
Grimes GJ,
Bokser AD,
Buhl R,
Crystal RG.
Glutathione aerosol suppresses lung epithelial surface inflammatory cell-derived oxidants in cystic fibrosis.
J Appl Physiol
1999;
87:
438-443
29. Grasemann H, Gaston B, Fang K, Paul K, Ratjen F. Decreased levels of nitrosothiols in the lower airways of patients with cystic fibrosis and normal pulmonary function. J Pediatr 1999; 135: 770-772 [Medline].
30.
Linnane SJ,
Keatings VM,
Costello CM,
Moynihan JB,
O'Connor CM,
Fitzgerald MX,
McLoughlin P.
Total sputum nitrate plus nitrite is
raised during acute pulmonary infection in cystic fibrosis.
Am J Respir
Crit Care Med
1998;
158:
207-212
31.
Grasemann H,
Ioannidis I,
Tomkiewicz RP,
de Groot H,
Rubin BK,
Ratjen F.
Nitric oxide metabolites in cystic fibrosis lung disease.
Arch
Dis Child
1998;
78:
49-53
32. Jones KL, Hegab AH, Hillman BC, Simpson KL, Jinkins PA, Grisham MB, Owens MW, Sato E, Robbins RA. Elevation of nitrotyrosine and nitrate concentrations in cystic fibrosis sputum. Pediatr Pulmonol 2000; 30: 79-85 [Medline].
33. Bird RB, Stewart WE, Lightfoot EN. Transport phenomena. New York: Wiley; 1960.
34. Kharitonov SA, Wells AU, O'Connor BJ, Cole PJ, Hansell DM, Logan-Sinclair RB, Barnes PJ. Elevated levels of exhaled nitric oxide in bronchiectasis. Am J Respir Crit Care Med 1995; 151: 1889-1893 [Abstract].
35. Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne EA, Barnes PJ. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994; 343: 133-135 [Medline].
36. Kelley TJ, Drumm ML. Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells. J Clin Invest 1998; 102: 1200-1207 [Medline].
37. Meng QH, Springall DR, Bishop AE, Morgan K, Evans TJ, Habib S, Gruenert DC, Gyi KM, Hodson ME, Yacoub MH, Polak JM. Lack of inducible nitric oxide synthase in bronchial epithelium: a possible mechanism of susceptibility to infection in cystic fibrosis. J Pathol 1998; 184: 323-331 [Medline].
38. Downey D, Elborn JS. Nitric oxide, iNOS, and inflammation in cystic fibrosis. J Pathol 2000; 190: 115-116 [Medline].
39.
Wechsler ME,
Grasemann H,
Deykin A,
Silverman EK,
Yandava CN,
Israel E,
Wand M,
Drazen JM.
Exhaled nitric oxide in patients with
asthma: association with NOS1 genotype.
Am J Respir Crit Care Med
2000;
162:
2043-2047
40.
Grasemann H,
Knauer N,
Buscher R,
Hubner K,
Drazen JM,
Ratjen F.
Airway nitric oxide levels in cystic fibrosis patients are related to a
polymorphism in the neuronal nitric oxide synthase gene.
Am J Respir
Crit Care Med
2000;
162:
2172-2176
41.
Lewis SM.
Emptying patterns of the lung studied by multiple-breath N2
washout.
J Appl Physiol
1978;
44:
424-430
42.
Silkoff PE,
Wakita S,
Chatkin J,
Ansarin K,
Gutierrez C,
Caramori M,
McClean P,
Slutsky AS,
Zamel N,
Chapman KR.
Exhaled nitric oxide
after beta2-agonist inhalation and spirometry in asthma.
Am J Respir
Crit Care Med
1999;
159:
940-944
43. Deykin A, Halpern O, Massaro AF, Drazen JM, Israel E. Expired nitric oxide after bronchoprovocation and repeated spirometry in patients with asthma. Am J Respir Crit Care Med 1998;157(3, Part 1):769-775.
44. Deykin A, Massaro AF, Coulston E, Drazen JM, Israel E. Exhaled nitric oxide following repeated spirometry or repeated plethysmography in healthy individuals. Am J Respir Crit Care Med 2000;161(4, Part 1): 1237-1240.
45. Bouhuys A. Respiratory dead space. In: Handbook of physiology. Bethesda, MD: The American Physiological Society; 1987. p. 699-714.
| |
APPENDIX |
|---|
Model Solution
Solution of the governing differential equations for the model leads to the following governing equation for the exhaled NO concentration (16):
|
(A1) |
where Vair is the volume of the airway compartment and residence time of each differential gas bolus in the airway compartment (
res) is the residence time of a differential gas bolus
in the airway compartment. Vair (ml) is approximated by the
physiological dead space, which is derived by subject age in
years plus ideal body weight in pounds (45). Equation A1 is
compared with the experimental data and used to estimate the
three remaining unknown parameters (JNO,max, DNO,air, and
Calv,ss) using nonlinear least-squares regression. Once values
for JNO,max, DNO,air, and Calv,ss are known, Equation A1 can be
used to predict the exhalation curves presented in Figure 6 or
to predict the CNO,plat at a constant exhalation flow rate (Table 2).
Airway Diffusing Capacity
It has been previously shown that DNO,air can theoretically be approximated by the following expression:
|
(A2) |
where
tiss:air is the tissue:air partition coefficient, k (s
1) is the
first-order rate constant that characterizes the rate of chemical
consumption by substrates such as superoxide, airway surface
area available for NO diffusion (cm2) (Aair) is the surface area
available for diffusion, molecular diffusivity of NO in the tissue
(
NO,tiss) (cm2/s) is the molecular diffusivity of NO in the tissue,
= Ltiss/
NO,tiss/k, and thickness of the tissue layer (cm) (Ltiss) is
the thickness of the tissue layer. The hyperbolic tangent (tanh) is
bounded between -1 and 1, and is a monotonically increasing
function of its argument. From Equation A2, DNO,air is a positive function of Aair,
tiss:air, DNO,tiss, and k, and is an inverse function of Ltiss. Values of Aair,
tiss:air,
NO,tiss, and Ltiss are 9,100 cm2,
0.0412, 3.3 × 10
5 cm2/s, and 0.01 cm as previously reported (16,
19). Equation A2 provides units of ml/s for DNO,air that are equivalent to pl s
1 ppb
1.
This article has been cited by other articles:
![]() |
D. Hubert, F. Aubourg, B. Fauroux, L. Trinquart, I. Sermet, G. Lenoir, A. Clement, A. T. Dinh-Xuan, B. Louis, B. Mahut, et al. Exhaled nitric oxide in cystic fibrosis: relationships with airway and lung vascular impairments Eur. Respir. J., July 1, 2009; 34(1): 117 - 124. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Condorelli, H.-W. Shin, A. S. Aledia, P. E. Silkoff, and S. C. George A simple technique to characterize proximal and peripheral nitric oxide exchange using constant flow exhalations and an axial diffusion model J Appl Physiol, January 1, 2007; 102(1): 417 - 425. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-W. Shin, C. D. Schwindt, A. S. Aledia, C. M. Rose-Gottron, J. K. Larson, R. L. Newcomb, D. M. Cooper, and S. C. George Exercise-induced bronchoconstriction alters airway nitric oxide exchange in a pattern distinct from spirometry Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2006; 291(6): R1741 - R1748. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-W. Shin, P. Condorelli, and S. C. George Examining axial diffusion of nitric oxide in the lungs using heliox and breath hold J Appl Physiol, February 1, 2006; 100(2): 623 - 630. [Abstract] [Full Text] [PDF] |
||||
![]() |
ATS Workshop Proceedings: Exhaled Nitric Oxide and Nitric Oxide Oxidative Metabolism in Exhaled Breath Condensate. Proceedings of the ATS, January 1, 2006; 3(2): 131 - 145. [Full Text] [PDF] |
||||
![]() |
H.-W. Shin, P. Condorelli, and S. C. George A new and more accurate technique to characterize airway nitric oxide using different breath-hold times J Appl Physiol, May 1, 2005; 98(5): 1869 - 1877. [Abstract] [Full Text] [PDF] |
||||
![]() |
ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005 Am. J. Respir. Crit. Care Med., April 15, 2005; 171(8): 912 - 930. [Full Text] [PDF] |
||||
![]() |
H.-W. Shin, P. Condorelli, C. M. Rose-Gottron, D. M. Cooper, and S. C. George Probing the impact of axial diffusion on nitric oxide exchange dynamics with heliox J Appl Physiol, September 1, 2004; 97(3): 874 - 882. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. George, M. Hogman, S. Permutt, and P. E. Silkoff Modeling pulmonary nitric oxide exchange J Appl Physiol, March 1, 2004; 96(3): 831 - 839. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Mahut, C. Delacourt, F. Zerah-Lancner, J. De Blic, A. Harf, and C. Delclaux Increase in Alveolar Nitric Oxide in the Presence of Symptoms in Childhood Asthma Chest, March 1, 2004; 125(3): 1012 - 1018. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-W. Shin, C. M. Rose-Gottron, D. M. Cooper, R. L. Newcomb, and S. C. George Airway diffusing capacity of nitric oxide and steroid therapy in asthma J Appl Physiol, January 1, 2004; 96(1): 65 - 75. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Tobin Pediatrics, Surfactant, and Cystic Fibrosis in AJRCCM 2002 Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 333 - 344. [Full Text] [PDF] |
||||
![]() |
H.-W. Shin and S. C. George Impact of axial diffusion on nitric oxide exchange in the lungs J Appl Physiol, December 1, 2002; 93(6): 2070 - 2080. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Proc. Am. Thorac. Soc. | Am. J. Respir. Cell Mol. Biol. |